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Abstract
Clear cell meningioma represents an uncommon variant of meningioma that typically affects children and young adults. 
Although an enrichment of loss-of-function mutations in the SMARCE1 gene has been reported for this subtype, compre-
hensive molecular investigations are lacking. Here we describe a molecularly distinct subset of tumors (n = 31), initially 
identified through genome-wide DNA methylation screening among a cohort of 3093 meningiomas, of which most were 
diagnosed histologically as clear cell meningioma. This cohort was further supplemented by an additional 11 histologically 
diagnosed clear cell meningiomas for analysis (n = 42). Targeted DNA sequencing revealed SMARCE1 mutations in 33/34 
analyzed samples, accompanied by a nuclear loss of expression determined via immunohistochemistry and a decreased 
SMARCE1 transcript expression in the tumor cells. Analysis of time to progression or recurrence of patients within the 
clear cell meningioma group (n = 14) in comparison to those with meningioma WHO grade 2 (n = 220) revealed a similar 
outcome and support the assignment of WHO grade 2 to these tumors. Our findings indicate the existence of a highly distinct 
epigenetic signature of clear cell meningiomas, separate from all other variants of meningiomas, with recurrent mutations 
in the SMARCE1 gene. This suggests that these tumors may arise from a different precursor cell population than the broad 
spectrum of the other meningioma subtypes.
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Introduction
Meningioma is the most common primary central nervous 
system (CNS) neoplasm, accounting for about a third of all 
brain tumors [10, 16]. Clear cell meningioma represents an 
uncommon variant of meningioma that typically affects chil-
dren and young adults [12, 21–23, 26]. Histologically, it is 
characterized by sheets of rounded or polygonal clear cells 
and perivascular and interstitial collagen [10]. Clear cell 
meningioma is associated with a more aggressive behavior 
[29] and is, therefore, classified as a World Health Organiza-
tion (WHO) grade 2 tumor [10]. Genetically, an enrichment 
of loss-of-function mutations in the SMARCE1 gene encod-
ing a subunit of the SWI/SNF chromatin remodeling com-
plex has been reported for this meningioma subtype [22, 23]. 
NF2 mutations, common in other meningiomas, are rare in 
this subtype [21]. Yet, it remains elusive whether clear cell 
meningioma is merely a morphological variant (albeit with 
prognostic implications) that can in principle be associated 
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with various driving alterations, or whether the predomi-
nance of SMARCE1 alterations rather points to a defining set 
of molecular underpinnings unique to these tumors.
Investigating the DNA methylation landscape of meningi-
omas, we identified a cluster of 31 tumor samples in a cohort 
of 3093 meningiomas (~ 1%) that formed a highly distinct 
group, well detached from the other meningiomas, of which 
most cases were diagnosed histologically as clear cell men-
ingioma. Based on this observation we collected additional 
morphologically identified clear cell meningiomas (n = 11) 
and performed further molecular workup on the whole 
cohort (n = 42) using DNA methylation profiling, targeted 
next-generation DNA sequencing and RNA sequencing.
Materials and methods
Sample collection
Tumor samples and retrospective clinical data from 42 
patients were provided by multiple national and interna-
tional collaborating centers and collected at the Department 
of Neuropathology of the University Hospital Heidelberg 
(Germany). Case selection was based on unsupervised hier-
archical clustering of genome-wide DNA methylation data 
in a cohort of 3,093 meningiomas that revealed a molecu-
larly distinct group of tumors comprising 31 samples, of 
which most were diagnosed histologically as clear cell men-
ingioma. Additionally, 11 histologically diagnosed clear cell 
meningiomas were subsequently integrated into analyses to 
verify that the specific cluster is made up by this subtype of 
meningioma. Analysis of tissue and clinical data was per-
formed in accordance with local ethics regulations. Clinical 
details of the patients are listed in Supplementary Table 1 
(online resource).
Immunohistochemistry
Immunohistochemistry was performed on a Ventana Bench-
Mark ULTRA Immunostainer (Ventana Medical Systems, 
Tucson, AZ, USA) for all cases with sufficient tissue (for 
EMA and SSTR2A n = 22; for SMARCE1 n = 25; for Ki-67 
n = 26). Antibodies were directed against: epithelial mem-
brane antigen (EMA; Clone GP1.4, mouse monoclonal, 
dilution 1:1000, Thermo Fisher Scientific, Fremont, CA, 
USA), somatostatin receptor 2A (SSTR2A; SS-8000-RM, 
rabbit monoclonal, dilution 1:10, Biotrend, Cologne, Ger-
many), Ki-67 (clone MIB-1, mouse monoclonal, 1:100 dilu-
tion, Dako Agilent, Santa Clara, CA, USA) and SMARCE1 
(HPA003916, rabbit polyclonal, dilution 1:700, Sigma-
Aldrich, St. Louis, MO, USA).
DNA methylation array processing and copy number 
profiling
Genomic DNA was extracted from formalin-fixed and par-
affin-embedded (FFPE) tissue samples. DNA methylation 
profiling of all samples was performed using the Infinium 
MethylationEPIC (850k) BeadChip (Illumina, San Diego, 
CA, USA) or Infinium HumanMethylation450 (450k) 
BeadChip array (Illumina) as previously described [2]. 
All computational analyses were performed in R version 
3.3.1 (R Development Core Team, 2016; https ://www.R-
proje ct.org). Copy-number variation analysis from 450k 
and EPIC methylation array data was performed using the 
conumee Bioconductor package version 1.12.0. Raw signal 
intensities were obtained from IDAT-files using the minfi 
Bioconductor package version 1.21.4 [1]. Illumina EPIC 
samples and 450k samples were merged to a combined 
data set by selecting the intersection of probes present on 
both arrays (combineArrays function, minfi). Each sample 
was individually normalized by performing a background 
correction (shifting of the 5% percentile of negative con-
trol probe intensities to 0) and a dye-bias correction (scal-
ing of the mean of normalization control probe intensities 
to 10,000) for both color channels. Subsequently, a cor-
rection for the array type (450k/EPIC) was performed by 
fitting univariable, linear models to the log2-transformed 
intensity values (removeBatchEffect function, limma pack-
age version 3.30.11). The methylated and unmethylated 
signals were corrected individually. Beta-values were 
calculated from the retransformed intensities using an 
offset of 100 (as recommended by Illumina). All samples 
were checked for duplicates by pairwise correlation of the 
genotyping probes on the 450k/850k array. To perform 
unsupervised non-linear dimension reduction, the remain-
ing probes after standard filtering [2] were used to calcu-
late the 1-variance weighted Pearson correlation between 
samples. The resulting distance matrix was used as input 
for t-SNE analysis (t-distributed stochastic neighbor 
embedding; Rtsne package version 0.13). The following 
non-default parameters were applied: theta = 0, pca = F, 
max_iter = 15,000 perplexity = 20.
Targeted next‑generation DNA sequencing 
and mutational analysis
Genomic DNA was extracted from FFPE tumor tis-
sue samples of 34 patients within the cohort using the 
automated Maxwell system with the Maxwell 16 FFPE 
Plus LEV DNA Purification Kit (Promega, Madison, 
WI, USA), according to the manufacturer’s instructions. 
Matched normal DNA was extracted from blood samples 
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of four of the affected individuals using the Maxwell 16 
Blood DNA Purification Kit (Promega). Capture-based 
next-generation DNA sequencing was performed on a 
NextSeq 500 instrument (Illumina) as previously described 
[18] using a custom brain tumor panel covering the entire 
coding and selected intronic and promoter regions of 130 
genes of particular relevance in central nervous system 
tumors. Reads were aligned against the reference genome 
(GRch37).
RNA sequencing and analysis
RNA was extracted from FFPE tissue samples using the auto-
mated Maxwell system with the Maxwell 16 LEV RNA FFPE 
Kit (Promega, Madison, WI, USA), according to the manufac-
turer’s instructions. Transcriptome analysis using messenger 
RNA (mRNA) sequencing of samples for which RNA of suf-
ficient quality and quantity was available (clear cell menin-
gioma (n = 15), NF2-mutant meningioma (n = 12)) was per-
formed on a NextSeq 500 (Illumina) as previously described 
[24]. Fastq files from transcriptome sequencing were used 
for de novo annotation of fusion transcripts using the defuse 
[14] and arriba (https ://githu b.com/suhri g/arrib a/) algorithms 
with standard parameters. Alignment to the human genome 
(GRCh37) was performed with the STAR aligner [4] and reads 
were then quantified using RSEM [9]. All further analysis was 
performed in R (version 3.6.0; R Core Team, 2019) using the 
DESeq2 package (version 1.26.0) [11]. Principal Component 
Analysis (PCA) was performed after variance stabilizing trans-
formation of the count data and normalization with respect to 
library size. Similarities between samples were determined by 
computing Manhattan distances on the variance stabilized data 
followed by unsupervised hierarchical clustering. Differential 
expression testing was performed on raw count data after fit-
ting a negative binomial model. P-values were adjusted for 
multiplicity by applying the Benjamini–Hochberg correction.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 8 
(GraphPad Software, La Jolla, CA, USA). Data on survival 
could be retrospectively retrieved for 14 patients. Distribu-
tion of time to progression or recurrence (TTP) after surgery 
was estimated by the Kaplan–Meier method and compared 
between groups with the log-rank test. P-values below 0.05 
were considered significant.
Results
DNA methylation profiling reveals a highly distinct 
epigenetic signature of clear cell meningioma
Investigating the DNA methylation landscape of menin-
giomas, we identified a group of 31 tumor samples in a 
cohort of 3093 meningiomas that formed a highly distinct 
cluster, well detached from the other meningiomas (Suppl. 
Figure 1, online resource). Intriguingly, most (18/31) cases 
in this initial cluster had been diagnosed histologically as 
clear cell meningioma, followed by atypical meningioma as 
the second most common diagnosis (Suppl. Table 1, online 
resource). Based on this observation we collected additional 
clear cell meningiomas based on their morphology (n = 11) 
that subsequently also all grouped with this specific cluster 
by DNA methylation profiling. A more focused t-distributed 
stochastic neighbor embedding (t-SNE) analysis of DNA 
methylation patterns confirmed the distinct nature of this 
group (Fig. 1). In contrast, none of the other meningioma 
subtypes with characteristic alterations, e.g. mutations in 
NF2, TRAF7/KLF4 or BAP1, or YAP1 fusion seem to form 
Fig. 1  t-distributed stochastic neighbor embedding (t-SNE) analy-
sis of DNA methylation profiles of the 42 clear cell meningiomas 
(ccMNG) alongside selected reference samples. Reference DNA 
methylation classes: meningioma benign (MNG_BEN), meningioma 
intermediate (MNG_INT), meningioma malignant (MNG_MAL), 
ependymoma posterior fossa group A (EPN_PFA), ependymoma pos-
terior fossa group B (EPN_PFB), ependymoma spinal (EPN_SPINE), 
solitary fibrous tumor/hemangiopericytoma (SFT_HMPC), schwan-
noma (SCHW), chordoma (CHORD) and secondary/metastatic mela-
noma (MELN)
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independent epigenetic clusters (Suppl. Figure 2, online 
resource). Analysis of copy number profiles derived from 
DNA methylation data revealed recurrent chromosomal 
aberrations within the clear cell meningioma group includ-
ing chromosome 17q (segmental) loss, chromosome 6q loss 
and chromosome 22q loss in approximately one-third of the 
cases (Suppl. Figure 3, online resource).
Clear cell meningiomas are characterized 
by mutations in SMARCE1
We next used targeted next-generation sequencing to gain 
insight into the mutational landscape of the meningiomas 
in this cluster and identified mutations in SMARCE1 in 
33 of the 34 cases (97%) with sufficient material available 
(Fig. 2 and Suppl. Table 1, online resource). Of the all in 
all 36 detected SMARCE1 mutations (three cases harbored 
two separate mutations), 32 were nonsense or frameshift 
mutations predicted to result in complete loss of the pro-
tein product (Fig. 2 and Suppl. Table 1, online resource). 
Immunohistochemical detection of SMARCE1 showed 
widespread nuclear loss of expression in the tumor cells 
in all analyzed cases (n = 25). The mutant allele frequency 
for the SMARCE1 mutations was highly variable (mean 
58%; range 30–90%), suggesting a possible biallelic loss 
of the gene at least in some cases. In four of the cases with 
matched normal DNA available, the SMARCE1 mutation 
was confirmed in the germline. Beside SMARCE1, no addi-
tional pathogenic mutations were detected (particularly none 
in the genes implicated in meningioma biology, including 
NF2, AKT1, KLF4, TRAF7, SMO, SUFU, PTCH1, BAP1, 
SMARCB1, PTEN, PIK3CA or TERT promoter mutations). 
In addition, screening of 705 meningioma samples with 
available sequencing and DNA methylation data revealed 
Fig. 2  Clinicopathological characteristics and recurrent genetic alterations of the 42 clear cell meningiomas (a). Visualization of the SMARCE1 
mutation profile in the investigated cohort was created using the online tool ProteinPaint  available at https ://prote inpai nt.stjud e.org/ (b)
285Acta Neuropathologica (2021) 141:281–290 
1 3
that SMARCE1 mutations occurred exclusively within the 
specific epigenetic class of clear cell meningiomas.
Differential gene expression segregates clear cell 
meningiomas and NF2‑mutant meningiomas
We next performed mRNA sequencing of 15 tumor sam-
ples within the specific clear cell cluster and 12 NF2-mutant 
meningioma samples for comparison. Gene expression 
variability within the cohort did not correlate with clinical 
parameters or anatomical location. Unsupervised hierarchi-
cal clustering (Fig. 3a) and PCA analysis (Fig. 3b) demon-
strated a clear segregation of tumor samples by DNA meth-
ylation profile and histology. In addition, quantification of 
mRNA expression confirmed decreased SMARCE1 expres-
sion in tumors within the clear cell cohort as compared to 
NF2-altered meningiomas (adjusted p = 1.34e-11; Fig. 3c). 
NF2 transcript levels were downregulated in NF2-mutant 
meningioma samples, respectively (adjusted p = 1.10e-
14; Fig. 3d). Interestingly, analysis of EZH2, the catalytic 
Fig. 3  Differences in gene expression profiles between clear cell 
meningiomas and NF2-mutant meningiomas. Normalized transcript 
counts from clear cell meningioma and NF2-mutant meningioma 
samples clustered by Pearson’s correlation coefficient (a) and princi-
pal component analysis (b). SMARCE1 (c) and NF2 (d) expression 
in clear cell meningiomas (n = 15) determined by RNA-sequencing 
compared to NF2-mutant meningioma samples (n = 12)
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subunit of the PRC2 complex which acts to antagonize the 
SWI/SNF complex, indicated an increased expression in 
clear cell meningiomas compared to meningiomas with NF2 
mutation (adjusted p = 1.70e-07; Suppl. Figure 4, online 
resource). Further differentially expressed genes between 
clear cell meningiomas and NF2-altered meningiomas are 
highlighted in supplementary Fig. 5 (online resource).
Clinical characteristics and morphological 
features within the molecularly defined clear cell 
meningioma cohort
The majority of the tumors in this molecular group 
(n = 29/42) were histologically diagnosed as clear cell 
meningioma (Suppl. Figure 1, online resource). Histo-
pathological review according to the WHO 2016 classi-
fication of tumors of the central nervous system for all 
cases with sufficient material confirmed these findings. All 
these tumors histologically showed clearly recognizable 
cellular areas composed of round to polygonal clear cells 
with perivascular and interstitial collagen corresponding to 
the typical histological features of clear cell meningioma 
(Fig.  4). All tumors exhibited immunohistochemical 
expression of EMA and SSTR2A (Fig. 4 and Suppl. Fig-
ure 1, online resource). Mitotic counts were generally 
low to moderate (between 0 and 1.7 mitosis per  mm2). 
Two tumors exhibited a higher count of up to 2.1 and 2.9 
mitoses per  mm2. The Ki-67 labeling index was very low 
(1–4%) in eight tumors, while 14 tumors had an elevated 
proliferation index of 5–10% and four of 15–20%. Con-
sistent with previous reports [23], clear cell meningiomas 
in our series were located in the spine (n = 17) as well as 
intracranially (n = 18). Median age at presentation in our 
cohort was 25 years (range 3–75) with a female predomi-
nance (F:M ratio 1.8:1). Outcome data were available for 
14 patients within the cohort. In comparison to a cohort 
of 458 meningiomas of other subtypes (WHO grade 1 and 
2) the prediction of outcome seems to be consistent with 
the current WHO grade 2 assignment: Time to recurrence 
in patients with clear cell meningiomas in our cohort was 
significantly worse than in patients with WHO grade 1 
meningiomas (p = 0.003; Fig. 5a) and not different from 
that in patients with other meningiomas of WHO grade 2 
(p = 0.63; Fig. 5b).
Fig. 4  Morphological and immunohistochemical features of clear 
cell meningiomas within the cohort. H&E staining of one of the clear 
cell meningiomas included in the investigated cohort showing a high 
cellularity of round to polygonal clear cells with perivascular and 
interstitial collagen. Immunohistochemical expression of EMA and 
SSTR2A as well as nuclear loss of SMARCE1 in the tumor cells
Fig. 5  Time to progression or 
recurrence (TTP) of 14 patients 
from the investigated cohort 
(ccMNG) for whom follow-up 
data were available compared to 
TTP of 238 patients with men-
ingioma WHO grade 1 (a) and 
220 patients with meningioma 
WHO grade 2 (b)
287Acta Neuropathologica (2021) 141:281–290 
1 3
Discussion
Besides confirming the known association of SMARCE1 
mutations and clear cell meningioma, our findings indicate 
the existence of a highly distinct epigenetic signature of 
this meningioma subtype. Given previous studies in multi-
ple tumor types on the robustness of cell-of-origin imprints 
in the epigenome of tumors [2, 6, 7, 25], this may suggest 
that these tumors arise from a different precursor cell popu-
lation than the broad spectrum of the other meningioma 
subtypes. Interestingly, none of the other meningioma sub-
types with characteristic alterations, e.g. mutations in NF2, 
TRAF7/KLF4 or BAP1, or YAP1 fusion, seem to form epi-
genetic clusters that are distinct to the same extent [19, 20]. 
However, given that SMARCE1 is itself a broad epigenetic 
regulator, this could explain why the DNA methylation 
profile in SMARCE1 deficient meningiomas is so different 
from that of other meningiomas. However, this finding will 
need confirmation in subsequent follow-up studies.
Although the clear cell subtype of meningioma repre-
sented the most common initial diagnosis in the primarily 
identified cohort, a smaller number of tumors were ini-
tially designated to other histological variants of menin-
gioma (in particular diagnosed as atypical meningioma 
WHO grade 2). However, a histopathological review for 
all cases with sufficient material confirmed clearly rec-
ognizable cellular areas composed of round to polygonal 
clear cells with perivascular and interstitial collagen cor-
responding to the typical histological features of clear cell 
meningioma in each of the analyzed tumors. On the other 
hand, none of the histologically diagnosed clear cell men-
ingiomas were found outside this specific cluster, which 
underlines a strong phenotype/genotype correlation. 
Therefore, in cases with diagnostic uncertainty immu-
nostaining for SMARCE1 and DNA methylation profiling 
may be useful for accurate diagnosis of this subtype.
As SMARCE1 mutations were detected in almost all 
tumors analyzed, it seems that clear cell meningiomas are 
primarily driven by these alterations. Germline loss-of-
function mutations in SMARCE1 were identified in familial 
spinal meningiomas in 2013 by Smith et al. [22] and seem to 
be highly linked to the clear cell subtype [23, 26]. SMARCE1 
encodes for a subunit of the SWI/SNF complex, which has 
been shown to play a widespread role in tumorigenesis [13, 
15]. Thus, SMARCE1 has been suggested as the potential 
oncogenic driver in clear cell meningioma [22]. Genetic 
alterations involving several other subunits of the SWI/SNF 
complex (in particular SMARCB1 and ARID1A) are found 
in meningioma pathogenesis and seem to be associated with 
more aggressive subtypes of meningioma [3]. In addition, 
PRC2, which acts to antagonize the SWI/SNF complex, is 
upregulated in higher-grade meningiomas [3, 5], which is 
consistent with our results. Inactivating mutations in SWI/
SNF subunits have been found in various other cancers, 
some of these demonstrating clear cell phenotype of the 
tumor cells as well [8, 17, 27, 28]. Interestingly, SMARCE1 
mutations seem to be restricted to this specific epigenetic 
class of clear cell meningiomas since no SMARCE1 altera-
tions were found in 705 other meningioma samples with 
available DNA methylation and sequencing data.
In line with our data, clear cell meningioma harboring 
a SMARCE1 mutation have been commonly described in 
children and young adults [26]. Interestingly though, the age 
range in our cohort was relatively wide considering such 
a molecularly homogeneous tumor, suggesting a possible 
cell-of-origin, which is present throughout life. Analysis of 
time to progression or recurrence of these patients in com-
parison to those with meningioma WHO grade 2 revealed a 
similar outcome and hence supports the assignment of WHO 
grade 2 to these tumors. Whether germline mutations in the 
SMARCE1 gene are associated with an increased risk for 
developing multiple meningiomas, as initially suggested 
[22], has to be determined in subsequent studies.
In summary, our data demonstrate a highly distinct epige-
netic signature of clear cell meningiomas, that is associated with 
frequent mutations within the SMARCE1 gene and/or loss of 
SMARCE1 protein expression, presumably by other mecha-
nisms. Whether or not this has further implications for tumor 
classification as a subtype versus an entity requires further study.
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